靶向CD45的抗体药物偶联物成功为小鼠同种异体造血干细胞移植提供预处理
研究报道一种靶向小鼠CD45的抗体药物偶联物(CD45-ADC),可在同基因和小差异移植模型中作为单药实现稳定的多系供者细胞植入,全供者嵌合与致死剂量全身照射相当。在主要组织相容性复合体(MHC)不匹配模型中,CD45-ADC联合低剂量全身照射及短程共刺激阻断可使89%受者获得稳定植入。
要点
- CD45-ADC(3 mg/kg)单药在同基因和小差异移植模型中实现与致死剂量全身照射相当的全供者嵌合。
- MHC不匹配模型中,CD45-ADC(3 mg/kg)联合低剂量全身照射(150 cGy)及抗CD40配体抗体使89%受者稳定植入。
- CD45-ADC(5 mg/kg)单药即可实现快速、高水平多系嵌合并维持至22周观察期。
核心结论
- CD45-ADC有潜力作为单药或与减低强度预处理联合,提供完全清髓性预处理的获益而毒性大幅降低。
研究设计与样本
- 小鼠同种异体造血干细胞移植研究,涵盖同基因、小差异和MHC不匹配移植模型。
主要发现
- CD45-ADC(3 mg/kg)单药在同基因和小差异移植模型中实现与致死剂量全身照射相当的全供者嵌合。
- MHC不匹配模型中,移植前CD45-ADC(3 mg/kg)联合低剂量全身照射(150 cGy)及短程抗CD40配体抗体共刺激阻断,89%受者获得稳定植入(均值72%)。
- CD45-ADC联合移植前全身照射(50 cGy)及移植后雷帕霉素、环磷酰胺或JAK抑制剂,分别有90%至100%受者获得稳定嵌合(均值分别为77%、59%、78%)。
- CD45-ADC(5 mg/kg)单药足以实现快速、高水平多系嵌合,并维持至22周观察期。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment of patients with nonmalignant or malignant blood disorders. Its success has been limited by graft-versus-host disease (GVHD). Current systemic nontargeted conditioning regimens mediate tissue injury and potentially incite and amplify GVHD, limiting the use of this potentially curative treatment beyond malignant disorders. Minimizing systemic nontargeted conditioning while achieving alloengraftment without global immune suppression is highly desirable. Antibody-drug-conjugates (ADCs) targeting hematopoietic cells can specifically deplete host stem and immune cells and enable alloengraftment. We report an anti-mouse CD45-targeted-ADC (CD45-ADC) that facilitates stable murine multilineage donor cell engraftment. Conditioning with CD45-ADC (3 mg/kg) was effective as a single agent in both congenic and minor-mismatch transplant models resulting in full donor chimerism comparable to lethal total body irradiation (TBI). In an MHC-disparate allo-HSCT model, pretransplant CD45-ADC (3 mg/kg) combined with low-dose TBI (150 cGy) and a short course of costimulatory blockade with anti-CD40 ligand antibody enabled 89% of recipients to achieve stable alloengraftment (mean value: 72%). When CD45-ADC was combined with pretransplant TBI (50 cGy) and posttransplant rapamycin, cyclophosphamide (Cytoxan), or a JAK inhibitor, 90% to 100% of recipients achieved stable chimerism (mean: 77%, 59%, 78%, respectively). At a higher dose (5 mg/kg), CD45-ADC as a single agent was sufficient for rapid, high-level multilineage chimerism sustained through the 22 weeks observation period. Therefore, CD45-ADC has the potential utility to confer the benefit of fully myeloablative conditioning but with substantially reduced toxicity when given as a single agent or at lower doses in conjunction with reduced-intensity conditioning.
引用
- Saha A, Hyzy S, Lamothe T, et al. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice. Blood. 2022. PMID: 34986233. doi:10.1182/blood.2021012366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。